Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David H. Sachs, M.D.

Co-Author

This page shows the publications co-authored by David Sachs and Frederic Preffer.
Connection Strength

0.403
  1. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24; 358(4):353-61.
    View in: PubMed
    Score: 0.093
  2. Dynamics of B Cell Recovery In Kidney/Bone Marrow Transplant Recipients. Transplantation. 2017 11; 101(11):2722-2730.
    View in: PubMed
    Score: 0.046
  3. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014 Jul; 14(7):1599-611.
    View in: PubMed
    Score: 0.036
  4. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant. 2011 Jul; 11(7):1464-77.
    View in: PubMed
    Score: 0.029
  5. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant. 2011 Jun; 11(6):1236-47.
    View in: PubMed
    Score: 0.029
  6. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation. 2010 Dec 27; 90(12):1607-15.
    View in: PubMed
    Score: 0.029
  7. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol. 2007 Jul; 35(7):1140-52.
    View in: PubMed
    Score: 0.022
  8. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007 Jul; 40(1):19-27.
    View in: PubMed
    Score: 0.022
  9. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006 Sep; 6(9):2121-33.
    View in: PubMed
    Score: 0.021
  10. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005 Feb; 128(3):351-9.
    View in: PubMed
    Score: 0.019
  11. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation. 2003 May 27; 75(10):1748-51.
    View in: PubMed
    Score: 0.017
  12. Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non-human primates. Transplantation. 2000 Jul 27; 70(2):368-74.
    View in: PubMed
    Score: 0.014
  13. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 2000; 6(3A):309-20.
    View in: PubMed
    Score: 0.013
  14. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999 May 22; 353(9166):1755-9.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.